Premium
Clinical study of l ‐asparaginase in the treatment of extranodal NK/T‐cell lymphoma, nasal type
Author(s) -
Yong Weiben
Publication year - 2016
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2207
Subject(s) - medicine , lymphoma , regimen , asparaginase , t cell lymphoma , clinical trial , oncology , leukemia , lymphoblastic leukemia
Extranodal natural killer/T‐cell lymphoma, nasal type, (ENKTL) is a rare distinct entity of non‐Hodgkin lymphoma. It is prevalent in Asia and Latin America but rare in North America and Europe. ENKTL represents an aggressive clinical course and a poor prognosis especially for advanced disease. There is no standard chemotherapeutic regimen for ENKTL. Recently, the efficacy of l ‐asparaginase in ENKTL has been confirmed. A series of l ‐asparaginase‐containing chemotherapeutic regimens have been studied in clinical trials and have significantly improved the efficacy and prognosis for patients with ENKTL. This review will focus on pharmacology of l ‐asparaginase, the efficacy of a series of l ‐asparaginase‐containing regimens in the treatment of ENKTL and future clinical study directions of l ‐asparaginase‐containing regimens in ENKTL. Copyright © 2015 John Wiley & Sons, Ltd.